APO RESEARCH · REPORT
Duchenne Muscular Dystrophy
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Product & engineering
Understand the product.
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Selected research
Industry Research
Duchenne Muscular Dystrophy Industry Research Report 2026
Market perspective
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
Read the full market overview
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.
Report Scope
This report quantifies the global Duchenne Muscular Dystrophy market in terms of revenue (US$ million) and, where applicable, sales volume (K Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Duchenne Muscular Dystrophy Market by Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy Segment by Type
Exondys 51
Emflaza
Translarna
Duchenne Muscular Dystrophy Segment by Application
Hospitals
Clinics
Home Care
Duchenne Muscular Dystrophy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Duchenne Muscular Dystrophy by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Duchenne Muscular Dystrophy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Exondys 51
- Emflaza
- Translarna
Applications
- Hospitals
- Clinics
- Home Care
Companies covered
- Sarepta Therapeutics
- PTC Therapeutics
- Pfizer
- Bristol-Myers Squibb
- Italfarmaco
- Santhera Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Duchenne Muscular Dystrophy Market Size (2021-2032)
- 2.2.2 Global Duchenne Muscular Dystrophy Sales (2021-2032)
- 2.2.3 Global Duchenne Muscular Dystrophy Market Average Price (2021-2032)
- 2.3 Duchenne Muscular Dystrophy by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Exondys 51
- 2.3.3 Emflaza
- 2.3.4 Translarna
- 2.4 Duchenne Muscular Dystrophy by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Home Care
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Duchenne Muscular Dystrophy Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Duchenne Muscular Dystrophy Sales (K Doses) of Manufacturers (2021-2026)
- 3.3 Global Duchenne Muscular Dystrophy Revenue of Manufacturers (2021-2026)
- 3.4 Global Duchenne Muscular Dystrophy Average Price by Manufacturers (2021-2026)
- 3.5 Global Duchenne Muscular Dystrophy Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Duchenne Muscular Dystrophy, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Duchenne Muscular Dystrophy, Product Type & Application
- 3.8 Global Manufacturers of Duchenne Muscular Dystrophy, Established Date
- 3.9 Global Duchenne Muscular Dystrophy Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sarepta Therapeutics
- 4.1.1 Sarepta Therapeutics Company Information
- 4.1.2 Sarepta Therapeutics Business Overview
- 4.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
- 4.1.5 Sarepta Therapeutics Recent Developments
- 4.2 PTC Therapeutics
- 4.2.1 PTC Therapeutics Company Information
- 4.2.2 PTC Therapeutics Business Overview
- 4.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
- 4.2.5 PTC Therapeutics Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Duchenne Muscular Dystrophy Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Bristol-Myers Squibb
- 4.4.1 Bristol-Myers Squibb Company Information
- 4.4.2 Bristol-Myers Squibb Business Overview
- 4.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
- 4.4.5 Bristol-Myers Squibb Recent Developments
- 4.5 Italfarmaco
- 4.5.1 Italfarmaco Company Information
- 4.5.2 Italfarmaco Business Overview
- 4.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Italfarmaco Duchenne Muscular Dystrophy Product Portfolio
- 4.5.5 Italfarmaco Recent Developments
- 4.6 Santhera Pharmaceuticals
- 4.6.1 Santhera Pharmaceuticals Company Information
- 4.6.2 Santhera Pharmaceuticals Business Overview
- 4.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
- 4.6.5 Santhera Pharmaceuticals Recent Developments
5 Global Duchenne Muscular Dystrophy Market Scenario by Region
- 5.1 Global Duchenne Muscular Dystrophy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Duchenne Muscular Dystrophy Sales by Region: 2021-2032
- 5.2.1 Global Duchenne Muscular Dystrophy Sales by Region: 2021-2026
- 5.2.2 Global Duchenne Muscular Dystrophy Sales by Region: 2027-2032
- 5.3 Global Duchenne Muscular Dystrophy Revenue by Region: 2021-2032
- 5.3.1 Global Duchenne Muscular Dystrophy Revenue by Region: 2021-2026
- 5.3.2 Global Duchenne Muscular Dystrophy Revenue by Region: 2027-2032
- 5.4 North America Duchenne Muscular Dystrophy Market Facts & Figures by Country
- 5.4.1 North America Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Duchenne Muscular Dystrophy Sales by Country (2021-2032)
- 5.4.3 North America Duchenne Muscular Dystrophy Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Duchenne Muscular Dystrophy Market Facts & Figures by Country
- 5.5.1 Europe Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Duchenne Muscular Dystrophy Sales by Country (2021-2032)
- 5.5.3 Europe Duchenne Muscular Dystrophy Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Duchenne Muscular Dystrophy Market Facts & Figures by Country
- 5.6.1 Asia Pacific Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Duchenne Muscular Dystrophy Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Duchenne Muscular Dystrophy Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Duchenne Muscular Dystrophy Market Facts & Figures by Country
- 5.7.1 South America Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Duchenne Muscular Dystrophy Sales by Country (2021-2032)
- 5.7.3 South America Duchenne Muscular Dystrophy Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Duchenne Muscular Dystrophy Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Duchenne Muscular Dystrophy Sales by Type (2021-2032)
- 6.1.1 Global Duchenne Muscular Dystrophy Sales by Type (2021-2032) & (K Doses)
- 6.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2021-2032)
- 6.2 Global Duchenne Muscular Dystrophy Revenue by Type (2021-2032)
- 6.2.1 Global Duchenne Muscular Dystrophy Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2021-2032)
- 6.3 Global Duchenne Muscular Dystrophy Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Duchenne Muscular Dystrophy Sales by Application (2021-2032)
- 7.1.1 Global Duchenne Muscular Dystrophy Sales by Application (2021-2032) & (K Doses)
- 7.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2021-2032)
- 7.2 Global Duchenne Muscular Dystrophy Revenue by Application (2021-2032)
- 7.2.1 Global Duchenne Muscular Dystrophy Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2021-2032)
- 7.3 Global Duchenne Muscular Dystrophy Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Duchenne Muscular Dystrophy Value Chain Analysis
- 8.1.1 Duchenne Muscular Dystrophy Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Duchenne Muscular Dystrophy Production Mode & Process
- 8.2 Duchenne Muscular Dystrophy Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Duchenne Muscular Dystrophy Distributors
- 8.2.3 Duchenne Muscular Dystrophy Customers
9 Global Duchenne Muscular Dystrophy Analyzing Market Dynamics
- 9.1 Duchenne Muscular Dystrophy Industry Trends
- 9.2 Duchenne Muscular Dystrophy Industry Drivers
- 9.3 Duchenne Muscular Dystrophy Industry Opportunities and Challenges
- 9.4 Duchenne Muscular Dystrophy Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst